Join a Study

This phase 1 clinical study is evaluating the safety and efficacy of the study medication, DONQ52.

This medication is designed to target an immune complex known to cause celiac disease symptoms. This may protect the small intestine of a person with celiac disease.

There is no gluten challenge in this study. You may be compensated for time and travel.

Requirements:

• You are 18-65 years old
• You have celiac disease
• You are already on a gluten-free diet
• You have had a diagnostic biopsy
• Other requirements will apply.

If you’re interested in the study, think you may qualify, or want to find a study site location near you, visit www.celiacdiseasestudy.com.

The goal of this phase 2 clinical trial is to test the safety and effects of the investigational medication PRV-015.

In combination with a gluten-free diet, PRV-015 aims to reduce symptoms and intestinal inflammation caused by accidental gluten exposure.

NO gluten challenge

Requirements:

• 18-70 years old
• Biopsy-confirmed celiac disease
• On a gluten-free diet for at least the last 12 months
• Still experiencing celiac disease symptoms

Learn more at proactiveceliac.com
Use referral code: REFCDF

Solutions for Celiac is a non-invasive research study for those with celiac disease. It involves a powder that is mixed with water and consumed with a meal. The study medication is designed to reduce symptoms of accidental gluten exposure while on a gluten-free diet.

Previous clinical trials involving this investigational treatment showed reduced damage to the intestine and reduced symptoms after a gluten challenge (compared to placebo).

Up to $1300 in compensation, plus qualified travel reimbursement. Contact us for more information: [email protected]

Learn More: SolutionsforCeliac.com

This study is a phase 1b/2 clinical trial testing the safety and tolerability of the investigational medication KAN-101.

KAN-101 targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens.

Requirements:

• 18-70 years
• Biopsy-confirmed celiac disease
• On gluten-free diet for at least the last 12 months

Learn more at clinicaltrials.gov/ct2/show/NCT05574010